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FDA Review
William F. McCarthy

Abstract

This paper provides a detailed example of how one should write the statistical
section of a bioequivalence study protocol for FDA review. Three forms of bioequivalence are covered: average bioequivalence (ABE), population bioequivalence (PBE) and individual bioequivalence (IBE). The method of analysis is based
on Jones and Kenward (2003) and a modification of their SAS Macro is provided.

Statistical Approach to Establishing Bioequivalence
If one assumes an orally administered drug is being considered, pharmacokinetics (PK) is
concerned with obtaining information on the absorption, distribution, metabolism and elimination
of the drug under consideration. PK is the study of what the body does to the drug. An important
outcome of a PK study is the assessment of how much of the active constituents of the drug
reaches its site of action. Since this type of assessment cannot be easily made, the concentration
of the drug under consideration that reaches the circulating bloodstream is taken as a surrogate.
This concentration of the drug in the blood is referred to as its bioavailability. Two drugs that have
the same bioavailability are termed bioequivalent.
Following FDA Guidelines, the statistical analysis should be based on the non-compartmental PK
parameters AUC0-t (Area Under the Curve from time 0 to last measurable time point), AUC0 to inf
(Area Under the Curve from time 0 to infinity) and Cmax (maximum concentration) derived from the
drug concentration-time curve.
Three Forms of Bioequivalence
In the following narrative, we refer to the original or innovator version of the drug under
consideration as the “Reference” or R. The new or alternative version of the drug we will refer to
as the “Test” or T.
1.

Average Bioequivalence (ABE):

To show that T and R are average bioequivalent it is only necessary to show that the mean
ln(AUC) and the mean ln(Cmax) for T is not significantly different from the mean ln(AUC) and the
mean ln(Cmax) for R.
In other words we need to show that, “on average”, in the population of intended patients, the two
drugs are bioequivalent.
This measure does not take into account the variability of T and R. It is possible for one drug to
be much more variable than the other, yet similar in terms of mean ln(AUC) and the mean
ln(Cmax).
It is for this reason that Population Bioequivalence (PBE) was introduced.
2.

Population Bioequivalence (PBE):

The measure of PBE is a mixture of the mean and variance of the ln(AUC) and the ln(Cmax).
PBE can be considered as a measure that permits patients who have not yet been treated with T
or R to be safely prescribed either.
3.

Individual Bioequivalence (IBE):

Two drugs could be similar in mean and variance over the population of potential patients, but be
such that they produce different effects when a patient is switched from formulation T to
formulation R or vice-versa.
In other words, there is a significant subject-by-formulation interaction.
To show that this is not the case T and R have to be shown to be Individual Bioequivalence (IBE).
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The measure of IBE is an aggregate measure involving the means and variances of T and R and
the subject-by-formulation interaction.
IBE can be considered as a measure that permits a patient who is currently being treated with R
to be safely switched to T.
NOTE: If T is IBE to R it does not imply that R is IBE to T.
Study Design
A replicated crossover design (four-period, two-sequence, two-formulation) will be used that will
allow for the assessment of ABE, PBE and IBE.
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Sample Size and Dropouts
Sample size determination was based on the use of the sample size tables provided in Appendix
C of the FDA Guidance Statistical Approaches to Establishing Bioequivalence (January 2001).
Please refer to Appendix A.
Since this document is a generic template, no specificity is provided in this section by this author.
In this section, the biostatistician using this template would add a narrative regarding estimated
sample size to use based on information from literature and/or pilot studies. The sample size
tables in Appendix A would be used and referenced. A discussion of dropouts would be
presented as well, with appropriate adjustments to sample size for such anticipated dropouts.
Method of Analysis
The methodology proposed by Jones and Kenward (2003) will be used to assess ABE, IBE and
PBE. For IBE and PBE, the FDA recommended aggregate metric for IBE and PBE is used.
For IBE the aggregate metric is:
2
2
( μT − μ R ) 2 + σ D2 + σ WT
− σ WR
2
max(0.04, σ WR
)

which tests the following linearized null hypotheses:
^ 2

if

2
2
σ WR > 0.04 then H 0 :ν IBE = δ 2 + σ D2 + σ WT
− (1 + CFDA )σ WR
≥ 0.

If

2
σ WR
≤ 0.04

^

then H 0 :ν C . IBE = δ + σ D + σ WT − σ WR − 0.04(CFDA ) ≥ 0 .
2

2

2

2
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The value CFDA in H 0 is a regulatory goalpost equal to 2.49. It assumes a within-subject
variance for R of 0.04, a difference of means of ln(1.25),

2
2
σ D2 =0.03 and σ WT
− σ WR
=0.02. The

denominator is set at 0.04.
Using the methodology proposed by Jones and Kenward (2003), the asymptotic upper bound of
the 90% confidence interval can be calculated as:
^

^

^

ν IBE + 1.645 Var[ν IBE ]

^

^

^

or ν C . IBE + 1.645 Var[ν C . IBE ] ,

where each component of the 90% confidence interval can be obtained from SAS code
developed by Jones and Kenward (2003).
If the asymptotic upper bound of the 90% confidence interval for both ln(AUC) and ln(Cmax) are
below zero, IBE can be claimed.

For PBE the aggregate metric is:

( μT − μ R ) 2 + σ T2 − σ R2
max(0.04, σ R2 )
where

2
2
2
2
2
σ T2 = σ WT
+ σ BT
, σ R = σ WR + σ BR .

which tests the following linearized null hypotheses:
^ 2

if

σ R > 0.04
^

If

σ R2 ≤ 0.04

then H 0 :ν PBE = δ + σ T − (1 + CFDA )σ R ≥ 0 .
2

2

2

then H 0 :ν C . PBE = δ + σ T − σ R − 0.04(CFDA ) ≥ 0 .
2

2

2

The value CFDA in H 0 is a regulatory goalpost equal to 1.75. It assumes a difference of means of
ln(1.25), and

σ T2 − σ R2 =0.02. The denominator is set at 0.04.

Using the methodology proposed by Jones and Kenward (2003), the asymptotic upper bound of
the 90% confidence interval can be calculated as:
^

^

^

ν PBE + 1.645 Var[ν PBE ]

^

^

^

or ν C . PBE + 1.645 Var[ν C . PBE ] ,

where each component of the 90% confidence interval can be obtained from SAS code
developed by Jones and Kenward (2003).
If the asymptotic upper bound of the 90% confidence interval for both ln(AUC) and ln(Cmax) are
below zero, PBE can be claimed.
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ABE is based on the “two one-sided test” (TOST), the asymptotic 90% confidence interval around
the geometric mean ratio of the test and reference formulations is required to fall within
bioequivalence limits of 0.80 to 1.25 (or ± 0.2231 on the natural log scale). If the asymptotic 90%
confidence interval around the geometric mean ratio of the test and reference formulations falls
within bioequivalence limits of 0.80 to 1.25 (or ± 0.2231 on the natural log scale) for both ln(AUC)
and ln(Cmax), ABE can be claimed.
The TOST results can be obtained from SAS code developed by Jones and Kenward (2003).
TOST is based on Schuirmann (1981; 1987).
Patterson and Jones (2002b, page 55) noted the following: “ Variance estimates are of less
concern in ABE testing, but in alternative criteria where estimates are important to interpretation
(i.e., for IBE and PBE) method-of-moments estimates should be viewed cautiously. Method-ofmoment estimation, as expected, yields unbiased estimates in complete data sets, but results in
^

positively biased

^

σ D2 in some sample with missing data. Bias in method-of-moment σ D2

(with

certain patterns of missing data) and constrained REML procedures increases as drugs become
more highly variable and decreases with increasing sample size. Biased method-of-moment
estimates in data sets with missing data exhibit a greater degree of bias than those found in CSH
REML, and the estimates from an alternative constrained (FAO(2)) REML are similarly
questionable. Only the unconstrained REML procedure (Type=’UN’) was found to yield unbiased
estimates for

2
2
σ D2 , σ WT
, and σ WR

in complete data sets and those with missing data.”

Strategy for Establishing Bioequivalence
With respect to FDA guidelines, bioequivalence is established for T if the following occurs:
•

When the individual BE approach is used, in addition to meeting the IBE limit based on
confidence bounds, the point estimate of the geometric test/reference mean ratio should
fall within 80-125%. In other words, both IBE and ABE need to be demonstrated for both
ln(AUC) and ln(Cmax).

•

When the population BE approach is used, in addition to meeting the PBE limit based on
confidence bounds, the point estimate of the geometric test/reference mean ratio should
fall within 80-125%. In other words, both PBE and ABE need to be demonstrated for both
ln(AUC) and ln(Cmax).

Since this document is a generic template, no specificity is provided in this section by this author.
In this section, the biostatistician using this template would add a narrative regarding which
approach would be used to demonstrate BE. Typically, one of the above approaches (highlighted
above with bullets) is used and the biostatistician should consult with FDA in terms of which
approach FDA would prefer to have used.
Statistical Modeling Issues
In general, replicated cross-over design trials that have been used to test for IBE and PBE have
used sample sizes in excess of 20 to 30 subjects (Patterson and Jones, 2002a). Therefore, it is
reasonable to consider asymptotic testing and there is a precedent for the use of such a
procedure in the study of pharmacokinetics (Machado et al., 1999). Thus, asymptotic normal
theory using restricted maximum likelihood (REML) will be used based on the modeling approach
outlined by Jones and Kenward (2003).

4
http://biostats.bepress.com/cobra/art30

All the appropriate estimates required to determine IBE, PBE and ABE can be obtained from the
use of SAS code, in particular, PROC MIXED using the REML option. In addition, using the
modeling approach outlined by Jones and Kenward (2003), an unstructured covariance structure
using the PROC MIXED option “Type=UN” is used. The FDA recommended reference-scaled
metric is used, in accordance with the FDA Guidance (2001). The Jones and Kenward (2003)
SAS code for assessing IBE, PBE and ABE is found in Appendix B.
Logarithmic Transformation
The FDA Guidance recommends that BE measures (e.g., AUC and Cmax) be log-transformed
using either common logarithms to base 10 or natural logarithms. This study will use the natural
logarithm. Per advice of the FDA Guidance, there will be no test for normality of the error
distribution after log-transformation.
Presentation of Data
In addition to the output from the Jones and Kenward (2003) SAS code for assessing IBE, PBE
and ABE, the drug concentration in biological fluid determined at each sampling time point will be
furnished on the original scale for each subject participating in the study. The pharmacokinetic
measures of systemic exposure will be furnished on the original scale. The mean, standard
deviation, and coefficient of variation for each pharmacokinetic measure will be computed and
tabulated in the final report.
The arithmetic mean and associated standard deviation for the T and R products and the
geometric means will be calculated.
To facilitate BE comparisons, the pharmacokinetic measures for each subject will be displayed in
parallel for the formulation tested. In particular, for each BE measure the ratio of the individual
geometric mean of the T product to the individual geometric mean of the R product will be
tabulated side by side for each subject. The summary tables will indicate in which sequence each
subject received the product.
Carryover Effects
It is assumed that carryover effects are either absent (the response to a formulation administered
in a particular period of the design is unaffected by formulations administered in earlier periods)
or equal for each formulation and preceding formulation.
Outlier Considerations
The FDA Guidance suggests that the existence of a subject outlier with no protocol violations
could indicate one of the following situations:
1. Product Failure – a subject exhibits an unusually high or low response to one or the other
products because of a problem with the specific dosage unit administered.
2. Subject-by-Formulation Interaction – a subject is representative of subjects present in the
general population in low numbers, for whom the relative bioavailability of the two
products is markedly different than for the majority of the population, and for whom the
two products are not bioequivalent, even though they might be bioequivalent in the
majority of the population.
If this type of data should occur, the sponsor will review how to handle such outliers with the
appropriate FDA review staff.
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Appendix A.
APPENDIX C of the FDA Guidance Statistical Approaches to Establishing Bioequivalence
(January 2001).

Sample Size Determination
Sample sizes for average BE should be obtained using published formulas. Sample sizes for
population and individual BE should be based on simulated data. The simulations should be
conducted using a default situation allowing the two formulations to vary as much as 5% in
average BA with equal variances and certain magnitude of subject-by-formulation interaction. The
study should have 80 or 90% power to conclude BE between these two formulations. Sample
size also depends on the magnitude of variability and the design of the study. Variance estimates
to determine the number of subjects for a specific drug can be obtained from the biomedical
literature and/or pilot studies.
Tables 1-4 below give sample sizes for 80% and 90% power using the specified study design,
given a selection of within-subject standard deviations (natural log scale), between-subject
standard deviations (natural log scale), and subject-by-formulation interaction, as appropriate.
Notation used below:

Δ = μT − μ R
μT = the true mean value of log(AUC) [or log(Cmax)] for T
μ R = the true mean value of log(AUC) [or log(Cmax)] for R
σ WT = within-subject standard deviation for T

σ WR = within-subject standard deviation for R
σ BT = between-subject standard deviation for T
σ BR = between-subject standard deviation for R
σ D = subject-by-formulation interaction standard deviation
2
2
σ D2 = σ BT
+ σ BR
− 2 ρσ BT σ BR
ρ = between-subject correlation of T and R
ε P = σ T2 − σ R2
2
2
σ T2 = σ WT
+ σ BT
2
2
σ R2 = σ WR
+ σ BR
2
2
ε I = σ D2 + σ WT
− σ WR
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Table 1
Average Bioequivalence
Estimated Numbers of Subjects
Δ =0.05
80% Power
90% Power
2P
4P
2P
4P
σ = σ =
WT

D

0.15

0.01
0.10
0.15

12
15
16

6
10
12

16
18
22

8
12
16

0.23

0.01
0.10
0.15

24
26
30

12
16
18

32
36
38

16
20
24

0.30

0.01
0.10
0.15

40
42
44

20
24
26

54
56
60

28
30
34

0.50

0.01
0.10
0.15

108
110
112

54
58
60

144
148
150

72
76
80

Results for the 2P (two-period) designs use the method of Diletti et al (1991).
Results for the 4P (four-period) designs use relative efficiency data of Liu (1995).
Table 2
Population Bioequivalence
Four-Period Design (RTRT/TRTR)
Estimated Numbers of Subjects
ε P =0.02, Δ =0.05

σ WR = σ WT

σ BR = σ BT

80% Power

90% Power

0.15

0.15
0.30

18
24

22
32

0.23

0.23
0.46

22
24

28
32

0.30

0.30
0.60

22
26

28
34

0.50

0.50
1.00

22
26

28
34

Results for population BE are approximate from simulation studies (1,540 simulations for each
parameter combination), assuming two-sequence,four-period trials with a balanced design across
sequences.
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Table 3
Individual Bioequivalence
Estimated Numbers of Subjects
ε I =0.05, Δ =0.05
80% Power
3P
4P

90% Power
3P
4P

σ WT =

σD =

0.15

0.01
0.10
0.15

14
18
28

10
14
22

18
24
36

12
16
26

0.23

0.01
0.10
0.15

42
56
76

22
30
42

54
74
100

30
40
56

0.30

0.01
0.10
0.15

52
60
76

28
32
42

70
82
100

36
42
56

0.50

0.01
0.10
0.15

52
60
76

28
32
42

70
82
100

36
42
56

Results for individual BE are approximate using simulations (5,000 simulations for each parameter
combination). The designs used in simulations are RTR/TRT (3P) and RTRT/TRTR (4P) assuming twosequence trials with a balanced design across sequences.
While the above sample sizes assume within-subject standard deviations, simulation studies for 3-period
and 4-period designs reveal that if Δ =0 and

2
2
σ WT
− σ WR
=0.05, the sample sizes given will provide either

80% or 90% power for these studies.
To maintain consistency with FDA requirements, which specify a minimum of 12 subjects in all BE
studies, the one case above where n=10 for 80% power should be increased to n=12.
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Table 4
Individual Bioequivalence
Estimated Numbers of Subjects
ε I =0.05, Δ =0.10
With Constraint on Δ (0.8 ≤ exp ( Δ ) ≤ 1.25)
80% Power 90% Power
4P
4P
σ = σ =
WT

0.30

D

0.01
0.10
0.15

30
36
42

40
48
56

0.50

0.01
34
46
0.10
36
48
0.15
42
56
Results for individual BE are approximate using simulations (5,000 simulations for each parameter
combination). The designs used in simulations are RTRT/TRTR (4P), assuming two-sequence trials with a
balanced design across sequences. When Δ =0.05, sample sizes remain the same as given in Table 3. This
is because the studies are already powered for variance estimation and inference, and therefore, a constraint
on the point estimate Δ has little influence on the sample size for small values of Δ .
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Appendix B.
Assessing ABE, PBE and IBE using SAS

/*******************************************************************/
/*
*/
/*
SAS Code for Assessing ABE, IBE and PBE
*/
/*
in Replicate Cross-over Trials
*/
/*
*/
/*
Jones and Kenward (2003) code
*/
/*
modified by W. McCarthy for this protocol
*/
/*
log(AUC) Model shown
*/
/*******************************************************************/
data bio2x4;
input subject sequence$ period form$ AUC CMAX;
logauc=log(AUC);
logcmax=log(CMAX);
datalines;
1 RTRT 1 R 5269 1366
1 RTRT 2 T 3848 1251
1 RTRT 3 R 3262 922
1 RTRT 4 T 4140 1101
. . . . . .
. . . . . .
. . . . . .
29 TRTR 1 T 2142 488
29 TRTR 2 R 1517 292
29 TRTR 3 T 2348 555
29 TRTR 4 R . .
;
run;
title 'data';
run;
title 'ABE, PBE and IBE for AUC, UNstructured covariance matrix,
KR adjusted df';
run;
proc mixed data=bio2x4 method=reml ITDETAILS CL=WALD ALPHA=0.1
scoring=50 maxiter=200 IC ASYCOV;
class sequence subject period form;
model logauc=sequence period form/ddfm=kenwardroger;
random form/type=UN subject=subject G;
repeated/group=form subject=subject;
lsmeans form/pdiff cl alpha=0.1;
estimate 'T-R'
form 1 -1 /CL ALPHA=0.1;
ods output Estimates=BLUEUN CovParms=COVUN AsyCov=ascovun;
run;
data covdun (keep=delta2 asigdel);
set blueun;
delta2=ESTIMATE*ESTIMATE;
asigdel=STDERR*STDERR;
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run;
data covunBT (keep=l_BT l_BTxw l_BTxBR l_BTxWT l_BTxWR);
set ascovun;
if COVPARM='UN(2,2)';
l_BT=COVP3; l_BTxw=COVP2;
l_BTxBR=COVP1; l_BTxWT=COVP5;
l_BTxWR=COVP4;
run;
data covunw (keep=l_w l_BRxw l_wxWT l_wxWR);
set ascovun;
if COVPARM='UN(2,1)';
l_w=COVP2;
l_BRxw=COVP1;
l_wxWT=COVP5;
l_wxWR=COVP4;
run;
data covunBR (keep=l_BR l_BRxWT l_BRxWR);
set ascovun;
if COVPARM='UN(1,1)';
l_BR=COVP1;
l_BRxWT=COVP5;
l_BRxWR=COVP4;
run;
data covunWT (keep=l_WT l_WTxWR);
set ascovun;
if COVPARM='Residual' and Row=5;
l_WT=COVP5;
l_WTxWR=COVP4;
run;
data covunWR (keep=l_WR);
set ascovun;
if COVPARM='Residual' and Row=4;
l_WR=COVP4;
run;
data blueUN (keep=undiff unlow unup unratio unrlow unrup);
set blueun;
undiff=ESTIMATE;
unratio=exp(undiff);
unlow=LOWER;
unrlow=exp(unlow);
unup=UPPER;
unrup=exp(unup);
run;
data bsigaun (keep=bsdaun bsigaun);
set covun; if
substr(COVPARM,1,6)='UN(2,2';
bsigaun=ESTIMATE;
bsdaun=SQRT(ESTIMATE);
run;
data bsigbun (keep=bsdbun bsigbun);
set covun;
if substr(COVPARM,1,6)='UN(1,1';
bsigbun=ESTIMATE;
bsdbun=SQRT(ESTIMATE);
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run;
data wsigaun (keep=wsdaun wsigaun);
set covun;
if substr(GROUP,6,1)='T';
wsigaun=ESTIMATE;
wsdaun=SQRT(ESTIMATE);
run;
data wsigbun (keep=wsdbun wsigbun);
set covun;
if substr(GROUP,6,1)='R';
wsigbun=ESTIMATE;
wsdbun=SQRT(ESTIMATE);
run;
data covun (keep=covun);
set covun;
if substr(COVPARM,1,6)='UN(2,1';
covun=ESTIMATE;
run;
data covun (keep=bsigaun bsdaun bsigbun bsdbun covun wsigaun
wsdaun wsigbun wsdbun sigdun rhoun);
merge bsigaun bsigbun wsigaun wsigbun covun;
sigdun=bsigaun+bsigbun-(2*covun);
rhoun=covun/(bsdaun*bsdbun);
run;
data ascovun (keep=v_ibeun v_cibeun f_ibeun f_cibeun ubibeun
ubcibeun v_pbeun v_cpbeun f_pbeun f_cpbeun ubpbeun
ubcpbeun);
merge covdun covunBT covunw covunBR covunWT covunWR covun;
theta=(((log(1.25))**2)+0.05)/0.04;
thetap=(((log(1.25))**2)+0.02)/0.04;
v_ibeun=delta2+sigdun+wsigaun-((1+theta)*wsigbun);
v_cibeun=delta2+sigdun+wsigaun-wsigbun-(0.04*theta);
f_ibeun=(4*asigdel*delta2)+l_BT+l_BR+(4*l_w)+l_WT+((1+theta)
*(1+theta)*l_WR)+(2*l_BTxBR)-(4*l_BTxw)+(2*l_BTxWT)(2*(1+theta)*l_BTxWR)-(4*l_BRxw)+(2*l_BRxWT)-(2*(1+theta)*
l_BRxWR)-(4*l_wxWT)+(4*(1+theta)*l_wxWR)-(2*(1+theta)*
l_WTxWR);
f_cibeun=(4*asigdel*delta2)+l_BT+l_BR+(4*l_w)+l_WT+l_WR+(2*l_BTxBR)(4*l_BRxw)+(2*l_BRxWT)-(2*l_BRxWR)-(4*l_wxWT)+(4*l_wxWR)(2*l_WTxWR);
ubibeun=v_ibeun+((probit(0.95))*sqrt(f_ibeun));
ubcibeun=v_cibeun+((probit(0.95))*sqrt(f_cibeun));
v_pbeun=delta2+bsigaun+wsigaun-((1+thetap)*(wsigbun+bsigbun));
v_cpbeun=delta2+bsigaun+wsigaun-(wsigbun+bsigbun)-(0.04*thetap);
f_pbeun=(4*asigdel*delta2)+l_BT+l_WT+((1+thetap)*(1+thetap)*l_BR)+
((1+thetap)*(1+thetap)*l_WR)+(2*l_BTxWT)(2*(1+thetap)*l_BTxBR)
-(2*(1+thetap)*l_BTxWR)-(2*(1+thetap)*l_BRxWT)-(2*(1+thetap)
*l_WTxWR)+(2*(1+thetap)*(1+thetap)*l_BRxWR);
f_cpbeun=(4*asigdel*delta2)+l_BT+l_WT+l_BR+l_WR+(2*l_BTxWT)-(2*l_BTxBR)
-(2*l_BTxWR)-(2*l_BRxWT)-(2*l_WTxWR)+(2*l_BRxWR);
ubpbeun=v_pbeun+((probit(0.95))*sqrt(f_pbeun));
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ubcpbeun=v_cpbeun+((probit(0.95))*sqrt(f_cpbeun));
run;
proc print data=ascovun;
var ubibeun ubcibeun ubpbeun ubcpbeun;
run;
Example of Edited Results from SAS OUTPUT

log(AUC0-t)
log(AUC0-inf)
log(Cmax)

Upper bound 90% CI
For FDA IBE Criterion
-0.0603
-0.0408
-0.0549
IBE claimed

Upper bound 90% CI
For FDA PBE Criterion
-0.2392
-0.1985
-0.1904
PBE claimed

TOST CI
For FDA ABE
0.8477, 0.9848
0.8200, 0.9600
0.7804, 0.9516
ABE not claimed

If upper bound for 90% CI for FDA IBE criterion for both log(AUC) and
log(Cmax) are below zero, IBE can be claimed.
If upper bound for 90% CI for FDA PBE criterion for both log(AUC) and
log(Cmax) are below zero, PBE can be claimed.
If TOST CI for both log(AUC) and log(Cmax) are contained within the limits of
0.80 to 1.25, ABE can be claimed.
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